Henlius Capitalizes On Biosimilar Launches

Company Plans To Expand Its Global Footprint and Production Capacity

Henlius has announced plans to expand its global footprint and bolster its manufacturing capacity after seeing its sales shoot up in 2020 based on three new launches.

Innovation
Henlius is pursuing innovation with its biologics pipeline • Source: Alamy

China’s Shanghai Henlius Biotech said that it “made the most out of recently launched products” in 2020, as the company announced a 546% increase in revenue to RMB587.6m ($89.8m) compared to 2019. The company said that 2020 marked a meaningful year for Henlius, as it “gathered pace in commercialization and continued the momentum for innovation.”

“The overall increase was mainly driven by the sales revenue from the launched products, R&D services provided to customers and...

More from Biosimilars

More from Products